Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 60 Neoplasm Metastasis 6 Neoplasms 4 Endometrial Neoplasms 4 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Ovarian Neoplasms 2 Neuroblastoma 2 Neoplasms by Site 2 Melanoma 2 Hereditary Sensory and Autonomic Neuropathies 2 Glioma 2 Glioblastoma 2 Carcinoma, Ovarian Epithelial 2 Breast Diseases 2 Anatomic Stage II Breast Cancer AJCC v8 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Sarcoma 1 Rhabdomyosarcoma 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Meningioma 1 Medulloblastoma 1

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 Fulvestrant 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × ribociclib × 1 year × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡